Aclaris医疗 ACRS 深 沪
已收盘 12-19 16:00:00 美东时间
3.14
+0.060
+1.95%
华盛通- 最 高3.475
- 今 开3.09
- 成交量 222.64万股
- 最 低 2.59
- 昨 收 3.08
- 总市值 2.09亿
- 52周最高 3.475
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.05
- 委 比 18.80%
- 总股本 6658.19万
- 历史最高 33.88
- 量 比 2.12
- 振 幅 28.73%
- 历史最低 0.5902
- 每 手 1
- 风险率 0.53%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
Aclaris Therapeutics has initiated a Phase 1a/1b trial for ATI-052, a potential best-in-class bispecific antibody targeting TSLP and IL-4R, to treat Th2-mediated inflammatory and allergic diseases. The trial includes a safety and dosing evaluation in healthy volunteers, followed by a proof-of-concept study in undisclosed indications. ATI-052 is designed to inhibit central proinflammatory pathways, with expected data from Phase 1a by late 2025 and Phase 1b in 2026.
06-23 10:59
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
Aclaris Therapeutics starts Phase 2 trial of bosakitug for moderate-to-severe atopic dermatitis. Bosakitug shows strong potency and affinity to TSLP, with top line results expected in H2 2026.
06-02 10:59
Aclaris Therapeutics to Participate in Two June Healthcare Conferences
Aclaris Therapeutics announced it will participate in two healthcare conferences in June. CEO Dr. Neal Walker and senior leaders will attend fireside chats at the Jefferies Global Healthcare Conference in New York on June 4, and the Goldman Sachs Global Healthcare Conference in Miami on June 11. Live and archived webcasts will be available on the company's website for 30 days.
05-28 13:20
HC Wainwright & Co. Reiterates Neutral on Aclaris Therapeutics
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Neutral.
2024-09-17 23:07
Aclaris Therapeutics Doses First Patient In Phase 2a Trial Of ATI-2138 For Moderate To Severe Atopic Dermatitis
The Phase 2a trial is an open-label study to investigate the safety, tolerability, pharmacokinetics, efficacy, and pharmacodynamics of ATI-2138 administered over 12 weeks in patients with moderate to severe atopic
2024-09-17 19:04
